T1	Participants 45 78	patients with chronic hepatitis C
T2	Participants 300 333	patients with chronic hepatitis C
T3	Participants 410 418	PATIENTS
T4	Participants 524 557	patients with chronic hepatitis C
T5	Participants 953 1001	patients in the control and the amantadine group
T6	Participants 1016 1029	control group
T7	Participants 1042 1059	amantadine group,
